| Literature DB >> 29445094 |
Juan Xia1, Zheng Tang1,2, Qinglong Deng1, Jiwei Wang3, Jinming Yu4.
Abstract
To examine the association between BMI and QOL in breast cancer survivors in China, we conducted a cross-sectional survey and recruited 10708 breast cancer survivors. Survivors self-reported QOL was measured using the EORTC QLQ-C30 and the QLQ-BR23. The impact of BMI on QOL was examined through standard least squares regression. Normal weight and overweight survivors were more likely to have a better QOL than underweight and obese survivors and the results were similar to survivors diagnosed as having chronic diseases. After adjustment for clinical and sociodemographic factors, the QOL increased with increasing BMI in breast cancer survivors ranged from underweight to overweight with no chronic diseases, especially in the scales of emotional function and fatigue. Obese breast cancer survivors reported a significantly worse QOL compared to normal weight and overweight breast cancer survivors. Within breast cancer survivors with one or more chronic diseases, it was more obvious that overweight ones had a significantly better QOL with clear evidence of a dose relationship across underweight to overweight in almost all scales. Unlike obese breast cancer survivors without chronic diseases, the ones with chronic disease(s) had a similar QOL compared to normal weight breast cancer survivors in all scales except in the domain of fatigue.Entities:
Mesh:
Year: 2018 PMID: 29445094 PMCID: PMC5813090 DOI: 10.1038/s41598-018-20392-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographic and Clinic Characteristics.
| Total (N = 10708) | Underweight (N = 366) | Normal (N = 7271) | Overweight (N = 2741) | Obesity (N = 330) | P | |
|---|---|---|---|---|---|---|
| Age, mean(SD), (yr) | 56.99 (5.50) | 56.41 (6.36) | 56.94 (5.50) | 57.19 (5.45) | 57.20 (5.92) | 0.030 |
| BMI, mean (SD) | 23.63 (3.20) | 17.36 (1.07) | 22.35 (1.65) | 26.79 (1.26) | 32.67 (3.74) | <0.001 |
| Married/cohabitating | 88.46 | 84.15 | 88.43 | 89.09 | 88.48 | 0.052 |
| Employment | 6.85 | 8.47 | 7.58 | 5.03 | 3.94 | <0.001 |
| Income | 22.53 | 21.58 | 23.35 | 20.76 | 20.30 | 0.090 |
| Years since diagnosis | 7.38 (5.95) | 7.51 (5.77) | 7.37 (5.89) | 7.39 (6.09) | 7.55 (6.29) | 0.722 |
| Tumor stage | 0.052 | |||||
| Stage I | 38.71 | 37.86 | 39.94 | 35.89 | 33.33 | |
| Stage II | 16.42 | 12.14 | 16.41 | 16.88 | 18.30 | |
| Stage III | 37.97 | 42.23 | 37.14 | 39.79 | 37.25 | |
| Stage IV | 6.91 | 7.77 | 6.51 | 7.44 | 11.11 | |
| Surgery | 98.37 | 98.55 | 98.44 | 98.44 | 97.58 | 0.313 |
| Radiotherapy | 46.08 | 41.28 | 45.36 | 46.20 | 52.39 | 0.001 |
| Chemotherapy | 91.43 | 87.74 | 91.22 | 92.11 | 91.60 | 0.034 |
| Endocrine therapy | 64.19 | 61.10 | 64.42 | 65.13 | 60.07 | 0.030 |
| Relapse | 7.24 | 9.78 | 6.72 | 7.99 | 9.66 | 0.011 |
| Metastasis | 7.16 | 8.10 | 6.78 | 7.58 | 11.08 | 0.019 |
| Drinking | 7.76 | 6.15 | 7.04 | 9.16 | 9.21 | 0.008 |
| Smoking: Never | 96.78 | 97.53 | 97.14 | 96.07 | 93.90 | 0.002 |
| Former | 2.39 | 2.47 | 2.12 | 2.90 | 3.96 | |
| Current | 0.84 | 0.00 | 0.75 | 1.03 | 2.13 | |
| Exercise | 75.56 | 72.73 | 75.92 | 76.05 | 66.77 | 0.001 |
| Sleeps | 19.33 | 25.82 | 19.51 | 17.90 | 19.94 | <0.001 |
| Comorbidity | <0.001 | |||||
| 0 | 29.15 | 39.34 | 32.68 | 20.36 | 13.03 | |
| 1 | 24.57 | 33.06 | 26.02 | 20.43 | 17.58 | |
| 2 | 19.28 | 15.03 | 18.83 | 20.87 | 20.91 | |
| ≥3 | 27.00 | 12.57 | 22.47 | 38.34 | 48.48 | |
| Hypertension | 26.57 | 10.77 | 22.21 | 37.70 | 48.30 | <0.001 |
| Hypertriglyceridemia | 31.47 | 17.08 | 27.48 | 42.07 | 48.46 | <0.001 |
| Hyperuricemia | 7.26 | 3.32 | 5.90 | 10.65 | 13.79 | <0.001 |
| Type I diabetes | 4.13 | 1.94 | 3.60 | 5.75 | 5.23 | <0.001 |
| Type II diabetes | 8.27 | 2.23 | 7.11 | 11.61 | 13.50 | <0.001 |
| CHD | 11.51 | 6.91 | 10.16 | 14.67 | 20.50 | <0.001 |
| Stroke | 3.31 | 1.94 | 3.11 | 3.61 | 6.96 | <0.001 |
| Respiratory system | 9.21 | 10.17 | 8.85 | 9.22 | 16.03 | 0.003 |
| H & G | 46.38 | 39.12 | 43.19 | 54.33 | 59.19 | <0.001 |
| Musculoskeletal | 24.43 | 18.28 | 22.11 | 30.10 | 36.36 | <0.001 |
1) Abbreviation: CHD, Coronary heart disease; H & G, Hepatobiliary & Gastrointestinal system;
2) Comorbidity: Sum of the total chronic diseases survivors suffered from.
QOL of breast cancer survivors according to BMI categories. Mean
| Adjusted scores | P | Differences between normal | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Underweight | Normal | Overweight | Obesity | Underweight | Overweight | Obesity | |||||
| t | Pr > |t| | t | Pr > |t| | t | Pr > |t| | ||||||
|
| |||||||||||
|
| |||||||||||
| QL | 61.32 | 65.61 | 67.57 | 65.37 | <0.001 | −3.48 | 0.003 | 3.64 | 0.002 | −0.19 | 1.000 |
| PF | 81.54 | 84.62 | 85.00 | 82.75 | <0.001 | −4.31 | <0.001 | 1.24 | 1.000 | −2.45 | 0.086 |
| EF | 82.93 | 83.76 | 85.49 | 84.24 | <0.001 | −0.90 | 1.000 | 4.35 | <0.001 | 0.49 | 1.000 |
| SF | 80.51 | 81.00 | 82.91 | 80.84 | 0.002 | −0.41 | 1.000 | 3.71 | 0.001 | −0.12 | 1.000 |
| RF | 88.31 | 90.35 | 90.90 | 90.66 | 0.064 | ||||||
| CF | 78.14 | 80.32 | 81.48 | 79.99 | 0.002 | −2.26 | 0.142 | 2.79 | 0.032 | −0.32 | 1.000 |
|
| |||||||||||
| BRSEF | 93.11 | 92.67 | 92.68 | 92.25 | 0.884 | ||||||
| BRSEE | 91.62 | 91.69 | 92.00 | 90.43 | 0.528 | ||||||
| BRBI | 66.60 | 67.33 | 67.76 | 66.04 | 0.607 | ||||||
| BRFU | 61.89 | 61.48 | 62.26 | 61.35 | 0.766 | ||||||
|
| |||||||||||
|
| |||||||||||
| FA | 31.67 | 25.91 | 23.63 | 23.42 | <0.001 | 5.86 | <0.001 | −5.34 | <0.001 | −2.37 | 0.107 |
| NV | 4.65 | 3.35 | 2.68 | 2.51 | <0.001 | 2.38 | 0.105 | −2.83 | 0.028 | −1.42 | 0.926 |
| PA | 19.09 | 15.75 | 15.36 | 17.09 | <0.001 | 3.58 | 0.002 | −0.97 | 1.000 | 1.34 | 1.000 |
| DY | 16.16 | 13.33 | 13.70 | 17.17 | <0.001 | 2.75 | 0.036 | 0.82 | 1.000 | 3.49 | 0.003 |
| SL | 22.54 | 19.53 | 17.41 | 19.92 | <0.001 | 2.71 | 0.040 | −4.44 | <0.001 | 0.32 | 1.000 |
| AP | 12.82 | 7.78 | 5.87 | 7.36 | <0.001 | 5.70 | <0.001 | −4.99 | <0.001 | −0.44 | 1.000 |
| CO | 12.13 | 10.36 | 8.29 | 8.68 | <0.001 | 1.73 | 0.498 | −4.68 | <0.001 | −1.53 | 0.755 |
| DI | 10.09 | 7.86 | 6.63 | 7.81 | <0.001 | 2.57 | 0.061 | −3.25 | 0.007 | −0.05 | 1.000 |
| FI | 30.20 | 28.39 | 28.16 | 32.26 | 0.099 | ||||||
|
| |||||||||||
| BRST | 17.99 | 16.76 | 15.88 | 16.47 | 0.004 | 1.80 | 0.432 | −2.98 | 0.017 | −0.40 | 1.000 |
| BRBS | 17.73 | 17.33 | 16.64 | 16.05 | 0.208 | ||||||
| BRAS | 21.76 | 22.16 | 23.87 | 25.88 | <0.001 | −0.36 | 1.000 | 3.55 | 0.002 | 3.14 | 0.010 |
| BRHL | 20.26 | 19.22 | 18.51 | 18.84 | 0.618 | ||||||
1) Abbreviations: QL, global health status; PF, physical function; EF, Emotional function; SF, Social function; RF, Role function; CF, Cognitive function; BRST, systemic therapy side effects; BRSEF, sexual function; BRSEE, sexual enjoyment; BRBI, body image; BRFU, future respective; FA, fatigue; NV, nausea and vomiting; PA, pain; DY, dyspnoea; SL, insomnia; AP, appetites loss; CO, constipation; DI, diarrhoea; FI, financial difficulties; BRBS, breast symptoms; BRAS, arm symptoms; BRHL, upset by hair loss.
2) Scores of QOL was analyzed by standard least squares adjustment for age, educational level, number of chronic diseases, marital status, residence conditions, occupation, relapse, transfer, exercise, use of alcohol and tobacco, breakfast, vegetable, fruits and sleeps condition;
3) Analysis of Variance was used to get the P Value. Bonferroni test was applied to analyze the difference between groups.
QOL of breast cancer survivors by BMI categories and status of chronic conditions. Mean.
| Adjusted scores | P | Differences between normal | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Underweight | Normal | Overweight | Obesity | Underweight | Overweight | Obesity | |||||
| t | Pr > |t| | t | Pr > |t| | t | Pr > |t| | ||||||
|
| |||||||||||
|
| |||||||||||
| QL | 65.90 | 68.96 | 70.38 | 55.63 | <0.001 | −1.58 | 0.691 | 1.29 | 1.000 | −3.92 | <0.001 |
| PF | 86.17 | 87.39 | 88.10 | 84.12 | 0.103 | ||||||
| EF | 84.33 | 86.12 | 88.38 | 77.21 | <0.001 | −1.24 | 1.000 | 2.78 | 0.033 | −3.48 | 0.003 |
| SF | 84.27 | 83.18 | 85.49 | 73.28 | 0.001 | 0.60 | 1.000 | 2.27 | 0.141 | −3.04 | 0.014 |
| RF | 91.12 | 91.64 | 92.39 | 91.06 | 0.742 | ||||||
| CF | 81.09 | 84.10 | 85.42 | 80.57 | 0.020 | −2.09 | 0.218 | 1.63 | 0.620 | −1.39 | 0.995 |
|
| |||||||||||
| BRSEF | 92.94 | 89.96 | 91.50 | 86.69 | 0.019 | 2.09 | 0.218 | 2.00 | 0.270 | −1.32 | 1.000 |
| BRSEE | 92.54 | 88.63 | 90.90 | 86.27 | 0.015 | 2.16 | 0.185 | 2.40 | 0.099 | −0.77 | 1.000 |
| BRBI | 71.83 | 71.57 | 73.48 | 65.57 | 0.148 | ||||||
| BRFU | 67.22 | 66.43 | 67.37 | 64.36 | 0.880 | ||||||
|
| |||||||||||
|
| |||||||||||
| FA | 24.14 | 20.86 | 18.06 | 24.49 | <0.001 | 2.17 | 0.181 | −3.29 | 0.006 | 1.34 | 1.000 |
| NV | 4.76 | 3.45 | 2.15 | 3.15 | 0.028 | 1.43 | 0.917 | −2.51 | 0.074 | −0.18 | 1.000 |
| PA | 12.68 | 11.65 | 11.04 | 18.35 | 0.026 | 0.76 | 1.000 | −0.81 | 1.000 | 2.78 | 0.033 |
| DY | 10.92 | 9.03 | 9.79 | 17.08 | 0.009 | 1.31 | 1.000 | 0.93 | 1.000 | 3.13 | 0.011 |
| SL | 16.08 | 14.63 | 12.74 | 19.14 | 0.035 | 0.91 | 1.000 | −2.12 | 0.205 | 1.59 | 0.670 |
| AP | 9.25 | 6.52 | 4.94 | 6.97 | 0.018 | 2.09 | 0.220 | −2.15 | 0.189 | 0.197 | 1.000 |
| CO | 11.39 | 7.59 | 5.59 | 10.86 | <0.001 | 2.77 | 0.033 | −2.61 | 0.055 | 1.33 | 1.000 |
| DI | 9.25 | 5.18 | 3.73 | 11.28 | <0.001 | 3.47 | 0.003 | −2.19 | 0.173 | 2.94 | 0.020 |
| FI | 26.25 | 26.71 | 25.97 | 43.13 | 0.006 | −0.18 | 1.000 | −0.50 | 1.000 | 3.41 | 0.004 |
|
| |||||||||||
| BRST | 14.28 | 12.83 | 12.49 | 17.94 | 0.017 | 1.40 | 0.978 | −0.58 | 1.000 | 2.78 | 0.033 |
| BRBS | 11.04 | 13.71 | 13.40 | 18.84 | 0.030 | −1.98 | 0.285 | −0.42 | 1.000 | 2.14 | 0.193 |
| BRAS | 16.75 | 17.51 | 18.42 | 27.05 | 0.006 | −0.48 | 1.000 | 1.02 | 1.000 | 3.39 | 0.004 |
| BRHL | 19.76 | 17.13 | 16.41 | 25.42 | 0.109 | ||||||
|
| |||||||||||
|
| |||||||||||
| QL | 58.83 | 64.19 | 66.46 | 66.23 | <0.001 | −3.37 | 0.005 | 3.68 | 0.001 | 1.42 | 0.934 |
| PF | 79.11 | 83.47 | 83.81 | 81.88 | <0.001 | −4.65 | <0.001 | 0.94 | 1.000 | −1.88 | 0.365 |
| EF | 82.37 | 82.78 | 84.44 | 84.65 | 0.002 | −0.35 | 1.000 | 3.63 | 0.002 | 1.74 | 0.487 |
| SF | 78.43 | 80.07 | 81.98 | 81.52 | 0.007 | −1.05 | 1.000 | 3.16 | 0.009 | 1.03 | 1.000 |
| RF | 86.71 | 89.81 | 90.36 | 90.31 | 0.040 | −2.49 | 0.077 | 1.15 | 1.000 | 0.45 | 1.000 |
| CF | 76.97 | 78.75 | 79.94 | 79.00 | 0.034 | −1.41 | 0.951 | 2.42 | 0.092 | 0.21 | 1.000 |
|
| |||||||||||
| BRSEF | 92.83 | 93.82 | 93.17 | 93.72 | 0.288 | ||||||
| BRSEE | 90.56 | 92.99 | 92.66 | 91.78 | 0.184 | ||||||
| BRBI | 64.21 | 65.61 | 65.61 | 64.89 | 0.842 | ||||||
| BRFU | 59.58 | 59.42 | 60.27 | 59.61 | 0.813 | ||||||
|
| |||||||||||
|
| |||||||||||
| FA | 35.30 | 27.98 | 25.85 | 24.63 | <0.001 | 5.72 | <0.001 | −4.31 | <0.001 | −2.90 | 0.023 |
| NV | 4.68 | 3.30 | 2.82 | 2.40 | 0.021 | 2.01 | 0.267 | −1.82 | 0.409 | −1.45 | 0.883 |
| PA | 22.42 | 17.47 | 17.03 | 17.78 | <0.001 | 4.01 | <0.001 | −0.91 | 1.000 | 0.28 | 1.000 |
| DY | 18.77 | 15.14 | 15.31 | 18.18 | 0.006 | 2.63 | 0.051 | 0.33 | 1.000 | 2.46 | 0.085 |
| SL | 25.58 | 21.50 | 19.44 | 21.43 | <0.001 | 2.77 | 0.033 | −3.66 | 0.002 | −0.05 | 1.000 |
| AP | 14.96 | 8.29 | 6.30 | 7.73 | <0.001 | 5.71 | <0.001 | −4.43 | <0.001 | −0.53 | 1.000 |
| CO | 11.83 | 11.51 | 9.40 | 9.10 | <0.001 | 0.23 | 1.000 | −3.93 | 0.001 | −1.92 | 0.333 |
| DI | 10.13 | 8.97 | 7.75 | 7.89 | 0.027 | 0.98 | 1.000 | −2.67 | 0.046 | −1.01 | 1.000 |
| FI | 32.49 | 29.11 | 28.90 | 30.99 | 0.299 | ||||||
|
| |||||||||||
| BRST | 19.61 | 18.40 | 17.30 | 17.15 | 0.003 | 1.35 | 1.000 | −3.19 | 0.009 | −1.55 | 0.728 |
| BRBS | 21.09 | 18.84 | 18.00 | 16.41 | 0.011 | 1.83 | 0.402 | −1.76 | 0.474 | −2.19 | 0.173 |
| BRAS | 23.92 | 24.08 | 25.94 | 26.72 | 0.005 | −0.11 | 1.000 | 3.24 | 0.007 | 1.98 | 0.289 |
| BRHL | 20.42 | 20.12 | 19.31 | 18.08 | 0.537 | ||||||
1) Abbreviations: QL, global health status; PF, physical function; EF, Emotional function; SF, Social function; RF, Role function; CF, Cognitive function; BRST, systemic therapy side effects; BRSEF, sexual function; BRSEE, sexual enjoyment; BRBI, body image; BRFU, future respective; FA, fatigue; NV, nausea and vomiting; PA, pain; DY, dyspnoea; SL, insomnia; AP, appetites loss; CO, constipation; DI, diarrhoea; FI, financial difficulties; BRBS, breast symptoms; BRAS, arm symptoms; BRHL, upset by hair loss.
2) Scores of QOL was analyzed by standard least squares, in None of the Chronic disease group, adjustment for age, educational level, marital status, residence conditions, occupation, relapse, transfer, exercise, use of alcohol and tobacco, breakfast, vegetable, fruits and sleeps condition; in combined with chronic diseases group, adjustment for the above factors and number of chronic diseases.
3) Analysis of Variance was used to get the P Value. Bonferroni test was applied to analyze the difference between groups.